Reuters logo
BRIEF-Biohaven completes enrollment in Spinocerebellar Ataxia clinical trial with Trigriluzole
May 30, 2017 / 7:10 AM / 4 months ago

BRIEF-Biohaven completes enrollment in Spinocerebellar Ataxia clinical trial with Trigriluzole

May 30 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd

* Biohaven completes enrollment in Spinocerebellar Ataxia clinical trial with Trigriluzole

* Biohaven completes enrollment in Spinocerebellar Ataxia clinical trial with Trigriluzole

* Says “we expect to submit a new drug application to FDA in early 2018.” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below